Table 2.
Side effects of severe COVID-19 patients received hUC-MSCs
Patient number | Liver function | Urea | Cr | Blood routine | ECG | Tumor marker# | Thrombotic/embolic | Impaired vision | Analysis | |
---|---|---|---|---|---|---|---|---|---|---|
ALT | AST | |||||||||
P1 | 25 | 37 | 4.96 | 60 | Normal | Normal | Norma | Normal | Normal | |
P2 | 29 | 23 | 6.14 | 82 | Normal | Normal | CA12-5 elevated* | Normal | Normal | Aged patient |
P3 | 33 | 39 | 3.92 | 77 | Normal | Normal | Normal | Normal | Normal | |
P4 | 15 | 18 | 3.44 | 57 | Normal | Normal | Normal | Normal | Normal | |
P5 | 11 | 34 | 3.50 | 50 | Normal | Normal | NSE elevated* | Normal | Normal | Slightly elevated |
P6 | 15 | 10 | 3.14 | 55 | Normal | Normal | Normal | Normal | Normal | |
P7 | 34 | 29 | 4.21 | 83 | Normal | Normal | Normal | Normal | Normal | |
P8 | 20 | 26 | 5.11 | 61 | Normal | Normal | Normal | Normal | Normal |
Normal range: ALT 9-50U/L; AST 15-40U/L; Urea 1.7–8.3 mmol/L; Cr 40–80 umol/L; CA12-5: 0–35 U/ml; NSE: 0–16.3 ng/ml
ECG Electrocardiogram, ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine
# Tumor marker includes: CEA, CA12-5, CA19-9, SCC, NSE, AFP, PSA (for males)
*CA12-5: 53 U/ml; NSE:18.5 ng/ml